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transfusion-free autologous stem cell transplantation protocol.
Methods: Seven patients were enrolled with malignancies that
would be treated with high dose chemotherapy. Four patients had
lymphoma, 1 patient had Ph acute lymphocytic leukemia, 1
patient had progressive CNS germinoma, and 1 patient had mul-
tiple myeloma. All patients underwent autologous stem cell trans-
plantation when in partial or complete remission. Patients entered
the study 8 weeks before anticipated stem cell transplantation and
received a regimen of recombinant erythropoietin, 40,000 U once
or twice weekly with the aim of achieving a hemoglobin level of 15
g/dL. G-CSF 10 g/kg was given for 5 days for stem cell mobili-
zation. High-dose therapy was disease-speciﬁc. Results: All pa-
tients suffered signiﬁcant pancytopenia, with no major side effects
in 6 of the 7 patients enrolled. One patient with progressive CNS
germinoma died from cerebral hemorrhage shortly after stem cell
infusion, but her platelet count was 31  109/L and hemoglobin
level was 16.4 g/dL before death. It is unlikely that her intracranial
hemorrhage was due purely to thrombocytopenia, but it may have
reﬂected tumor necrosis secondary to chemotherapy. The other
patients all remain in complete remission to date. They are now
45, 36, 24, 9, 5, and 1 months status posttransplanta-
tion. Conclusion: Autologous stem cell transplantation is a feasi-
ble treatment option for Jehovah’s Witness patients. Refusal of
blood product support should not be considered an absolute con-
traindication for high-dose chemotherapy and autologous stem cell
transplantation.
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HPC IN PERIPHERAL BLOOD PREDICTS CFU ACTIVITY AND TIME TO
ENGRAFTMENT IN AUTOLOGOUS APHERESIS PBSC PRODUCTS AS EF-
FECTIVELY AS CD34 CELL COUNT
Creer, M.H.1, Regan, D.M.2, Saridey, S.K.3, Oliver, D.A.4 1Depart-
ment of Pathology, Saint Louis University, Saint Louis, MO; 2Saint
Louis Cord Blood Bank, Saint Louis, MO; 3Department of Internal
Medicine, Saint Louis University,Saint Louis, MO; 4Saint Louis Uni-
versity Cancer Center, Saint Louis, MO.
In autologous PBSC products collected after growth factor mo-
bilization, previous studies have shown that measurements of HPC
correlate with CD34 cell count in peripheral blood (PB) before
apheresis collection. Because CFU activity in the ﬁnal product is
expected to be a standard measure of HSC/HPC content, we
compared the HPC and CD34 counts in PB before collection with
CFU in the ﬁnal product, to determine the utility of preapheresis
HPC in identifying patients likely to produce a suitable product.
By measuring CD34 and total MNC cell content in PB before
collection, midway through collection, and in the ﬁnal product, we
found that the ratio of CD34/MNC remained constant. This
demonstrates that recovery of progenitor cells and MNC is iden-
tical throughout collection and processing. This observation allows
calculation of expected CFU content in the ﬁnal product based on
preapheresis HPC and CD34 measurements. Using the observed
product ratio of CFU/CD34 (0.192  0.102) and the expected
product ratio of CFU/HPC (0.113  0.060) (n  25 for both
values), we compared the predicted product CFU content based on
observed HPC and CD34 cell count in preapheresis peripheral
blood with the actual CFU content recovered in the ﬁnal product.
Results: Autologous products (n  12) from 10 patients were
compared between CFU (106) predicted by peripheral blood HPC
(median, 21; range, 0–416) and CD34 (median, 11; range, 0–165)
with actual CFU (median, 23; range, 4–131) obtained on the ﬁnal
product (P .08; Freidman test). A strong linear association was
noted between actual CFU and preaphersis HPC (Spearman rank
correlation  0.84). Conclusion: This pilot study suggests that
HPC in peripheral blood predicts CFU content as effectively as
CD34. For 75% of the samples, the observed CFU and the CFU
predicted by HPC was higher than the CFU predicted by CD34,
possibly indicating a CD34 fraction that is capable of colony
formation and that can be measured by the HPC parameter.
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EXPERIENCES OF PERIPHERAL BLOOD STEM CELLS COLLECTION
FROM RADIAL ARTERY FOR UNRELATED DONOR TRANSPLANTATION
Chen, R.L., Ro, Y.C., Yeh, S.Y., Lin, D.Y., Hsu, W.L. Buddhist Tzu
Chi Stem Cells Center, Hualien, Taiwan.
Many donors with inadequate peripheral venous access were
encountered in our center. Central venous access was an alternative
method of peripheral blood stem cell (PBSC) collection but posed
signiﬁcant risks to donors. Although the frequency of progenitor
cells in the radial arteries was reduced in comparison to that in the
central veins, probably associated with pulmonary PBSC trapping,
the impact on clinical PBSC transplantation may be negligible.
The experiences of 27 PBSC unrelated donors who had inadequate
peripheral venous access and were collected from radial arterial
line are reported. There were 18 males and 9 females, ranging in
age from 23 to 52 years (median, 29 years). The body weight of
donors ranged from 50 to 106.5 kg (median, 63 kg); that of
recipients, from 20 to 103 kg (median, 62 kg). All donors were
treated with 4–5 days of ﬁlgramstim at an approximate dose of 10
mg/kg/day and underwent 1–2 days of apheresis with a continuous-
ﬂow blood cell separator. Preapheresis white cell and platelet
counts were 37.5  8.9  109/mL and 196  36  109/mL,
respectively. Calcium gluconate replacement was administered
while the patients complained of numbness. A total of 19.2  6.6
L of blood was processed per donor. Collection took 5.9  2.1
hours per donor. A total of 501  155  108 nucleated cells and
347  188  106 CD34 cells per donor were collected. These
yielded 8.7  3.6  108 total nucleated cells and 6.0  3.5  106
CD34 cells/kg of the recipient weight. None of PBSC donors
was noted to have laboratory hypocalcemia. The platelet count
ranged from 95 to 179  109/mL (median, 132) immediately
postapheresis, which corresponded to a decrease of 55  27 
109/mL. Two donors still experienced anorexia, headache, malaise,
or myalgia 1 week postapheresis, but none did 1 month posta-
pheresis. The white cell count, lymphocyte count, and platelet
count 1 month postapheresis was 5.5 1.5 109/mL, 1.7 0.4
109/mL, and 227  45  109/mL, respectively. Engraftment rate
of recipients was 100% after exclusion of 2 early deaths (1 before
and another 6 days after PBSC infusion). PBSC collection from a
radial arterial line might be acceptable for unrelated donor trans-
plantation when the donor has inadequate peripheral venous ac-
cess.
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EFFECT OF THE NUMBER OF DAYS REQUIRED FOR COLLECTION OF
ALLOGENEIC PERIPHERAL BLOOD STEM CELLS ON ENGRAFTMENT
Devetten, M.P., Lynch, J.C., Petersen, K.A., Kessinger, A. University of
Nebraska Medical Center, Omaha, NE.
The use of peripheral blood stem cells (PBSCs) for allogeneic
transplantation continues to increase. The relationship between
ease of mobilization of PBSC and engraftment after transplanta-
tion has not been extensively studied. We retrospectively analyzed
the relationship between days of collection by apheresis (catego-
rized as 1, 2, and  2) and engraftment in 109 matched sibling
donor/recipient pairs who underwent collection between March
1995 and November 2003. All donors recieved G-CSF at 10 g/kg
for 4 days, with collection started on the ﬁfth day. Daily G-CSF
administration and collection were continued until a minimum of
3  106 CD34 cells/kg per recipient had been collected. Cells
were frozen and stored in DMSO until infusion. All grafts were
unmanipulated, and all recipients received G-CSF posttransplan-
tation. Fifty-one donors (47%) required 1 day to collect an ade-
quate graft, 52 donors (48%) required 2 days, and 6 donors (6%)
required  2 days. Females were more likely to require  1 day of
collection (P  .01). Donors who required  2 days for collection
were older than donors who required only 1 or 2 days (P  .015).
There was no association between days required for collection and
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donor body size measurements (height, weight, body surface area),
or between days required for collection and recipient body size
measurements. There was a statistically signiﬁcant association be-
tween product characteristics (CD34 cell dose, CFU-GM, MNC
cell dose) and number of collection days (P  .01 for CD34, P 
.001 for CFU-GM, and P  .0001 for MNC). For CD34 cell
dose ( 106/kg) the median number of cells collected was 6.56
(range, 3.1–21.1) for 1 day collection, 7.3 (range, 3.0–24.9) for 2
days collection, and 3.2 (range, 1.8–5.9) for  2 days collection.
The number of collections was not signiﬁcantly related to engraft-
ment in univariate analysis. However, after adjustment for CD34
dose infused (using Cox regression), the number of collection days
was signiﬁcantly related to platelet engraftment (P  .05), but not
to neutrophil engraftment (P  .17) or red cell engraftment (P 
.94). We conclude that all donors were able to mobilize sufﬁcient
cells for engraftment, but that grafts requiring  2 collections are
associated with a delay in platement engraftment after correction
for CD34 cell dose.
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PREDICTIVE FACTORS FOR ADEQUATE HEMATOPOIETIC STEM CELL
MOBILIZATION WITH HEMATOPOIETIC GROWTH FACTOR ALONE IN
PATIENTS WITH LYMPHOMA
Tomblyn, M., Rogers, T., Arora, M., Barker, J., Brunstein, C.,
Burns, L., Kaufman, D., McGlave, P., Miller, J., Slungaard, A.,
Weisdorf, D. University of Minnesota Division of Hematology, Oncology,
and Transplantation, Minneapolis, MN.
There are no deﬁned factors to reliably predict which patients
will mobilize sufﬁcient progenitor cells with hematopoietic growth
factor (HGF) alone. Furthermore, it is unclear whether HGF
mobilization impedes subsequent chemotherapy mobilization. To
address this question, we prospectively evaluated 175 patients with
lymphoma enrolled from January 1996 to August 2004. All patients
were mobilized with G-CSF (250 g/m2/day), followed by a sec-
ond mobilization with chemotherapy (cyclophosphamide, mitox-
antrone, cytarabine) and G-CSF (250 g/m2/day). Using HGF
alone, 58 patients (33%) patients collected  2  106 CD34
cells/kg, whereas 90 patients (51%) collected  2  106 CD34
cells/kg with only chemotherapy mobilization. Sixty-four patients
(37%) collected 2 106 CD34 cells/kg after mobilization with
either HGF or chemotherapy. Of these poor mobilizers, 41 (64%)
had combined collections totalling  2  106 CD34 cells/kg.
The median number of collections in each group was 3 (HGF, 2–4;
chemotherapy, 1–8). The median yield of PBSC collected with
HGF alone was 58% of that obtained with chemotherapy mobili-
zation (1.37  106 CD34 cells/kg [0.12–10.1] vs 2.37  106
CD34 cells/kg [0.0–100.7]; P  .0001). Some 55% of patients
had better mobilization with chemotherapy than with HGF, and
another 15% had equivalent collections ( 0.5  106 CD34
cells/kg). Variables analyzed included age, disease type, stage at
diagnosis, numbers and cycles of previous chemotherapy regimens,
presence of bone marrow involvement at any time, previous radi-
ation, and length of time from diagnosis to the ﬁrst day of HGF
harvest. In univariate analysis, patients with stage IV disease at
diagnosis (odds ratio [OR] 0.5 [0.24–1.02]; P .06) and a longer
interval between diagnosis and harvest (OR  0.85 [0.71–1.01];
P  .06) had a lower likelihood of adequate collection when
mobilized with HGF alone. When evaluating only the patients
who collected  2  106 CD34 cells/kg by either method,
multivariate analysis demonstrated that stage IV disease and within
the subset of patients with Hodgkin’s lymphoma, older age and a
longer interval to harvest predicted a poorer collection with HGF
alone. There is no evidence that the use of HGF mobilization
hinders the ability to later collect PBSC with chemotherapy mo-
bilization. Based on these data, and to spare potential toxicity and
expense of chemotherapy mobilization, it may be reasonable to
attempt HGF mobilization in lymphoma patients with earlier-
stage disease or a shorter time from diagnosis to harvest.
Table 1. Multivariate Analysis Predicting Patients that are Poor
Mobilizers with HGF Alone*
OR (95% CI) p-Value
Stage of Disease
Stage I–III —
Stage IV 0.30 (0.11–0.80) p < 0.02
Patients with Hodgkin
Lymphoma (n  57)
Increasing Age (10 year
increments) 0.23 (0.06–0.90) p < 0.04
Increasing Interval from
Diagnosis to Harvest
(12 month increments) 0.18 (0.03–0.91) p < 0.04
*Includes only patients collecting 2  106 with either HGF or
chemotherapy mobilization.
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EFFICIENT ENRICHMENT AND FLOW SORTING OF ALDEHYDE DEHY-
DROGENASE BRIGHT HEMATOPOIETIC PROGENITOR CELLS FROM
THAWED, BANKED UMBILICAL CORD BLOOD
Gentry, T.L.1, Balber, A.E.1, Baucom, C.1, Deibert, E.1, Haley, N.R.1,
Pritchard, C.1, Hickerson, D.1, Carawan, H.2, Kaestner, A.2,
Kurtzberg, J.2 1StemCo Biomedical, Durham, NC; 2Duke University
Medical Center, Durham, NC.
Almost all of the hematopoietic progenitor cells that durably
reconstitute NOD/SCID mice and the majority of long-term and
short-term multilineage colony initiating cells in fresh human
umbilical cord blood (UCB) can be isolated by ﬂow-sorting
low-side scatter cells that express high levels of the enzyme
aldehyde dehydrogenase (ALDHbrSSClo). Such highly enriched
ALDHbrSSClo cell populations may be useful in expansion of UCB
stem cells and other clinical applications. These clinical prepara-
tions of UCB stem cells are likely to be derived from UCB that has
been frozen, banked, and then thawed to manufacture a therapeutic
preparation. We explored ways to prepare thawed UCB for ﬂow
sorting using ALDESORT and other markers. Frozen UCB units
banked using the COBLT method and designated for research
use under approved institutional protocols were thawed and
washed in dextran/albumin. Several protocols were explored for
removing RBCs without signiﬁcantly reducing the number of
ALDHbrSSClo. Successful immunomagnetic depletion of RBCs
was achieved with antiglycophorin A, clone 2B7 (anti-GlyA) and of
monocyte lineage cells with anti-CD14, clone BA-8 using EasySep
(TM, StemCell Technologies, Inc.). Treatment of thawed, washed
UCB preparations (n  36) with this method removed 99.5% of
the RBCs and 73% of the mononuclear cells, and permitted re-
covery of 77% of the ALDHbrSSClo cells, for a net 3.2-fold
enrichment of the ALDHbrSSClo population. The resulting RBC/
nucleated cell ratio in the depleted preparations was  2; these
preparations could be used with ALDESORT for subsequent ﬂow
sorting. After depletion with anti-GlyA and anti-CD14, no mea-
surable residual iron from the EasySep reagent and very low levels
of mouse immunoglobulin were detected in the cell preparation
before sorting. The method did not damage cells, because  99%
of the cells in the cell preparation excluded 7-aminoactinomycin D.
Hematopoietic colony-forming cells were enriched 6-fold pre-
EasySep to post-EasySep depletion. Flow-sorted ALDHbrSSClo
populations prepared using anti-GlyA and anti-CD14 with
EasySep were enriched 39-fold for 14-day hematopoietic colony-
forming cells relative to whole thawed cords and have been used
successfully in ex vivo expansion protocols. Collectively, these
results suggest that this method could be developed to manufacture
cell preparations from banked, thawed UCB that will prove suit-
able for clinical use.
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